<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 30 May 2021 07:34:07 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>《药品检查管理办法（试行）》发布</title><link>https://mp.weixin.qq.com/s/0isRMc8YAmr4BV4h-hJsXA</link><description></description><content:encoded><![CDATA[《药品检查管理办法（试行）》发布]]></content:encoded><pubDate>Sat, 29 May 2021 19:47:30 +0800</pubDate></item><item><title>PD-1/PD-L1 抑制剂的剂量选择与优化</title><link>https://mp.weixin.qq.com/s/FJd_xerZOaB5AR189GT6NA</link><description></description><content:encoded><![CDATA[PD-1/PD-L1 抑制剂的剂量选择与优化]]></content:encoded><pubDate>Sat, 29 May 2021 19:47:30 +0800</pubDate></item><item><title>一文理清！最全肿瘤标志物解读！</title><link>https://mp.weixin.qq.com/s/_swb6AeS2GUlvbuqFXD3_g</link><description></description><content:encoded><![CDATA[一文理清！最全肿瘤标志物解读！]]></content:encoded><pubDate>Sat, 29 May 2021 19:47:30 +0800</pubDate></item><item><title>重磅！全球首个新冠灭活疫苗Ⅲ期临床数据正式发表</title><link>https://mp.weixin.qq.com/s/uXCJSJLKobz61_gvzHeJiw</link><description></description><content:encoded><![CDATA[重磅！全球首个新冠灭活疫苗Ⅲ期临床数据正式发表]]></content:encoded><pubDate>Fri, 28 May 2021 08:00:25 +0800</pubDate></item><item><title>NMPA发布：执业药师电子注册证来了，长这样</title><link>https://mp.weixin.qq.com/s/Uo4OF7ezxahLDM3vH536FQ</link><description></description><content:encoded><![CDATA[NMPA发布：执业药师电子注册证来了，长这样]]></content:encoded><pubDate>Fri, 28 May 2021 08:00:25 +0800</pubDate></item><item><title>深度解读：后新冠时代，疫苗研发未来可期（内含福利）</title><link>https://mp.weixin.qq.com/s/M0XL03g1Ul0B44HaRvKFJQ</link><description></description><content:encoded><![CDATA[深度解读：后新冠时代，疫苗研发未来可期（内含福利）]]></content:encoded><pubDate>Fri, 28 May 2021 08:00:25 +0800</pubDate></item><item><title>药典委关于2020年版药典相关问题的解读（一）</title><link>https://mp.weixin.qq.com/s/fj8quovXI3SAs2Zk3Suzzg</link><description></description><content:encoded><![CDATA[药典委关于2020年版药典相关问题的解读（一）]]></content:encoded><pubDate>Fri, 28 May 2021 08:00:25 +0800</pubDate></item><item><title>原料药中稳定性试验应该怎么做？</title><link>https://mp.weixin.qq.com/s/kMyiyOBUqZkvpGbhWH1phg</link><description></description><content:encoded><![CDATA[原料药中稳定性试验应该怎么做？]]></content:encoded><pubDate>Wed, 26 May 2021 21:38:37 +0800</pubDate></item><item><title>【DIA好声音】抗肿瘤联合用药开发策略考量</title><link>https://mp.weixin.qq.com/s/WXYVr2XSokv39-WklUCudQ</link><description></description><content:encoded><![CDATA[【DIA好声音】抗肿瘤联合用药开发策略考量]]></content:encoded><pubDate>Wed, 26 May 2021 21:38:37 +0800</pubDate></item><item><title>国外药品审评专家咨询制度在药品审评体系中的作用及思考</title><link>https://mp.weixin.qq.com/s/qFF2HzUGHRA9KErAL_hhvQ</link><description></description><content:encoded><![CDATA[国外药品审评专家咨询制度在药品审评体系中的作用及思考]]></content:encoded><pubDate>Wed, 26 May 2021 21:38:37 +0800</pubDate></item><item><title>肺癌抗血管生成药物大盘点</title><link>https://mp.weixin.qq.com/s/TXGj-JXd57fk-mPQJfUl9w</link><description></description><content:encoded><![CDATA[肺癌抗血管生成药物大盘点]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>一文讲透美国DMF</title><link>https://mp.weixin.qq.com/s/ZhnGHxZZXPLynRk9kmTmnA</link><description></description><content:encoded><![CDATA[一文讲透美国DMF]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>什么是生物制品批签发？</title><link>https://mp.weixin.qq.com/s/B-bvUCtQBP9l86dVFXayLw</link><description></description><content:encoded><![CDATA[什么是生物制品批签发？]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>谈谈中国的CAR-T发展</title><link>https://mp.weixin.qq.com/s/ZWimvyZqzX89nmM4n9WUDQ</link><description></description><content:encoded><![CDATA[谈谈中国的CAR-T发展]]></content:encoded><pubDate>Mon, 24 May 2021 21:59:07 +0800</pubDate></item><item><title>2021生物制品工艺开发及放大实战培训班</title><link>https://mp.weixin.qq.com/s/9xXsiDUaiYKbY0IYGYh3JQ</link><description></description><content:encoded><![CDATA[2021生物制品工艺开发及放大实战培训班]]></content:encoded><pubDate>Mon, 24 May 2021 21:59:07 +0800</pubDate></item><item><title>美欧日复杂注射剂技术要求及案例分析</title><link>https://mp.weixin.qq.com/s/qU7M45eFFyOib5jeb4mTPQ</link><description></description><content:encoded><![CDATA[美欧日复杂注射剂技术要求及案例分析]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>CDE-CTD共性问题汇总及解答</title><link>https://mp.weixin.qq.com/s/r9BEe_va51EfDG_0QEpmvA</link><description></description><content:encoded><![CDATA[CDE-CTD共性问题汇总及解答]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>疫苗临床开发和注册中的毒性研究</title><link>https://mp.weixin.qq.com/s/jBAqzoDKSqCCJI9s3OqMzw</link><description></description><content:encoded><![CDATA[疫苗临床开发和注册中的毒性研究]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>高端制剂是改良型新药的最优解</title><link>https://mp.weixin.qq.com/s/7i1e4hsYQwEpX4i0epupkA</link><description></description><content:encoded><![CDATA[高端制剂是改良型新药的最优解]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>2020年版药典相关问题的解读（一）</title><link>https://mp.weixin.qq.com/s/Y-rmiBFlwdizT5ZEIDMcyA</link><description></description><content:encoded><![CDATA[2020年版药典相关问题的解读（一）]]></content:encoded><pubDate>Sat, 22 May 2021 20:21:59 +0800</pubDate></item></channel></rss>